Million Women Study

Million Women Study
Title	Million Women Study
Authors	Dame Valerie Beral, Isabella Ford, Sarah Darby, Jane Green, others
Country	United Kingdom
Institution	University of Oxford, Cancer Research UK, Medical Research Council
Funding	UK Department of Health, British Heart Foundation, Cancer Research UK
Participants	~1,000,000 women
Started	1996
Status	ongoing (longitudinal follow-up)

Million Women Study

The Million Women Study is a large-scale, prospective cohort investigation of women's health conducted primarily in the United Kingdom beginning in 1996. Designed to examine risk factors for cancer and other chronic diseases, the study recruited about one million women through the National Health Service (United Kingdom) breast screening program and has produced influential analyses linking hormone therapy, smoking, body size, alcohol, and reproductive factors to disease outcomes. Key investigators include Dame Valerie Beral and collaborators at institutions such as University of Oxford and Cancer Research UK.

Introduction

The study was established to address major unanswered questions about the etiology of cancers and chronic diseases among middle-aged and older women. Recruitment utilized invitations sent via the National Health Service (United Kingdom) breast screening program, enrolling women born before 1950 and providing baseline questionnaires about reproductive history, medical history, lifestyle, and hormone use. The cohort has been linked to routine datasets including the Office for National Statistics, regional cancer registries, and hospital episode statistics to enable long-term follow-up for incidence and mortality outcomes.

Study Design and Methods

This prospective cohort study collected baseline data between 1996 and 2001, with follow-up through record linkage and repeat questionnaires. Participants completed baseline forms covering exposures such as use of menopausal hormone replacement therapy, smoking, alcohol consumption, body mass index, and reproductive factors. The study design nested case–control analyses and prospective comparisons, employing methods such as Cox proportional hazards models and stratified analyses to estimate relative risks. Linkage to datasets from entities including the General Register Office for Scotland, NHS Central Register, and regional cancer registries provided outcome ascertainment for cancers, cardiovascular events, and mortality. Data management and statistical analysis were overseen by teams at University of Oxford and collaborating centers such as University of Cambridge.

Key Findings

Analyses from the cohort yielded multiple high-impact findings. A prominent result quantified the increased breast cancer risk associated with menopausal hormone therapy, differentiating risks by preparation types and durations; these conclusions were central to debates involving the National Institute for Health and Care Excellence and were cited in reports by World Health Organization panels. Research also implicated alcohol consumption in breast cancer risk, while demonstrating associations between body mass index and postmenopausal breast cancer and between smoking and lung cancer incidence. The study produced important data on cervical cancer screening effectiveness when combined with findings from the Department of Health (UK), and shed light on ovarian cancer epidemiology in relation to reproductive history. Results concerning hormone therapy influenced clinical guidance from organizations including the Royal College of Physicians and informed public communications by Cancer Research UK.

Public Health Impact and Policy Changes

Findings prompted rapid reassessment of hormone replacement therapy use in several countries, contributing to changes in prescribing practice and public health guidance. The evidence influenced policy discussions at bodies such as the National Health Service (United Kingdom), National Institute for Health and Care Excellence, and international agencies like the World Health Organization. Media coverage engaged major outlets including reports tied to statements from Department of Health (UK) officials and consumer information campaigns by Cancer Research UK. Screening and prevention programs for breast and cervical cancer incorporated nuanced risk communication informed by study results, and clinicians in organizations such as the Royal College of Obstetricians and Gynaecologists adapted counseling practices regarding menopausal therapies.

Criticisms and Limitations

Critiques focused on potential selection bias from recruitment via the National Health Service (United Kingdom) breast screening program and on reliance on self-reported exposures at baseline. Observational design limitations—including residual confounding and changes in exposure over time—were noted by methodologists at institutions such as London School of Hygiene & Tropical Medicine. Some commentators from journals like The Lancet and British Medical Journal debated interpretation of hormone therapy subgroup analyses and generalizability to populations outside the United Kingdom. The predominantly middle-aged and older female sample limited applicability to younger women and to non-UK healthcare contexts represented by entities like the Centers for Disease Control and Prevention and the National Institutes of Health.

Legacy and Subsequent Research

The cohort remains a cornerstone dataset for women's health epidemiology, informing subsequent investigations into hormone therapy, lifestyle risk factors, and cancer prevention. Data sharing and collaboration have extended to consortia including the Breast Cancer Association Consortium and meta-analyses alongside cohorts from United States, Norway, Sweden, and Australia. Methodological lessons influenced large-scale studies such as the UK Biobank and contributed to statistical best practices promoted by groups at University College London. Ongoing follow-up continues to generate publications addressing long-term outcomes, survivorship, and interactions between genetics and environment in partnerships with genomic projects like the International Cancer Genome Consortium.

Category:Epidemiological studies